A systematic review of moral reasons on orphan drug reimbursement.

ABSTRACT:

Background

The number of market approvals of orphan medicinal products (OMPs) has been increasing steadily in the last 3 decades. While OMPs can offer a unique chance for patients suffering from rare diseases, they are usually very expensive. The growing number of approved OMPs increases their budget impact despite their low prevalence, making it pressing to find solutions to ethical challenges on how to fairly allocate scarce healthcare resources under this context. One potential solution could be to grant OMPs special status when considering them for reimbursement, meaning that they are subject to different, and less stringent criteria than other drugs. This study aims to provide a systematic analysis of moral reasons for and against such a special status for the reimbursement of

SUBMITTER: Zimmermann BM 

PROVIDER: S-EPMC8247078 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature